跳到主要內容

Sinha Vikas 的 Form 4/A 修正申報

修正

Verona Pharma plc(VRNA),2025/5/22 申報

申報編號
0001104659-25-051979
申報時間
2025/5/22
交易日
2025/4/29
申報延遲
23 天
10b5-1 計畫
有勾選
原始申報日
2025/5/1

這份申報列了 4 筆非衍生性交易、2 筆衍生性交易。公開市場賣出合計 $142.7 萬。交易後 23 天申報。

這份修正申報取代了 0001104659-25-043644(2025/5/1 申報)。

申報人

一份 Form 4 可以有好幾位申報人,例如本人與他控制的基金。各交易表上顯示的是第一位。

這份申報的申報人
申報人與公司的關係
Sinha VikasCIK 0001337845董事

非衍生性證券(表 I)

普通股等股票的取得與處分,每一列是申報上的一筆。

非衍生性證券的交易
交易日證券交易股數價格金額交易後持股持有方式旗標
2025/4/29Ordinary SharesM行使選擇權取得+120,384$1.70+$204,652.8194,824直接
2025/4/29Ordinary SharesS賣出處分−120,384$8.92−$1,073,825.2874,440直接
2025/4/29Ordinary SharesM行使選擇權取得+39,616$0.50+$19,808114,056直接
2025/4/29Ordinary SharesS賣出處分−39,616$8.92−$353,374.7274,440直接

衍生性證券(表 II)

選擇權、認股權證、限制型股票單位等。股數是標的股票的股數;單價與金額是衍生證券本身的價格,交易後持有是衍生證券的單位數。

衍生性證券的交易
交易日證券交易標的股數單價金額交易後持有持有方式旗標
2025/4/29Ordinary SharesM行使選擇權處分−120,384$0.00$00直接
2025/4/29Ordinary SharesM行使選擇權處分−39,616$0.00$0160,384直接

附註與備註

本站收錄交易價格引用的附註、修正申報(Form 4/A)的全部附註,以及申報的備註。其他附註,例如間接持有的方式、交易計畫的細節,請看 SEC EDGAR 上的原文。

F1

This Form 4 amendment is being filed to correct the Reporting Person's Form 4 filed on May 1, 2025 which erroneously presented all transacted securities in American Depositary Shares ("ADSs") instead of Ordinary Shares.

F2

Reported securities are represented by ADSs, each of which represents eight (8) Ordinary Shares of the Issuer.

F3

The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction adopted by the Reporting Person on November 6, 2024, solely with the intent to cover payment of the exercise price.

F4

Consists of 74,440 Ordinary Shares represented by 9,305 ADSs.

F5

The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by ADSs, each of which represents eight (8) Ordinary Shares of the Issuer.

F6

The option is fully vested.

看 SEC EDGAR 上的完整原文 (在新分頁開啟)